It is exemplified by therapies that inhibit the PD-1/PD-L1 axis to enhance cytotoxic T cell activity and suppress tumor growth, resulting in response rates up to 45% in advanced NSCLC patients [46]. The gene discussed is CD274; the disease is neoplasm.